An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment
Introduction
Complete surgical resection is currently the only potentially curative treatment for a pancreatic adenocarcinoma [1]; however, only 10–15% of patients benefit from such treatment because their symptoms present late in the disease, and thus, the diagnosis is performed at a locally advanced or metastatic stage in more than 80% of cases [2]. Pancreatic resection is not indicated in cases of advanced disease because this intervention has a high morbidity and mortality, does not improve survival, and may compromise the quality of life of patients who already have a short life expectancy [3].
Although the prognosis of a pancreatic adenocarcinoma remains poor, much progress toward the treatment of this disease has been made in recent years. Improved imaging techniques and a higher spatial resolution have enabled us to better capture the regional and distant spreading of these cancers. Systematic resection of the retroportal pancreatic lamina associated with the possibility of vascular resection has increased the potential for complete surgical resection [4]. Furthermore, the marking of the resection limits by the surgeon in the operating room and the systematic analysis of the posterior edges have enabled us to standardize and optimize histological analysis [5].
Another major advance is the use of preoperative chemoradiotherapy, which may be responsible for a “downstaging” of the tumor in about 30% of patients, allowing us to extend surgical approaches to locally advanced lesions [6]. In these cases, the rates of complete resection and survival are close to those that are found in patients who immediately undergo surgery [7]. Thus, the implementation of neoadjuvant chemoradiotherapy is increasingly recommended as the first-line treatment for locally advanced pancreatic adenocarcinomas, especially those that are classified as “borderline” [8].
The assessment of locoregional extensions in pancreatic cancer is currently largely based on computed tomography (CT) analysis because the negative predictive value of this modality is high (89–100%) [9]; however, local changes that are secondary to chemotherapy and radiotherapy and due to inflammation, fibrosis, or necrosis may be difficult to evaluate or quantify by CT [10]. Very few studies have focused on the semiological patterns of CT scans and the reliability of the scanner in the context of reevaluating the resectability of a tumor after preoperative treatment. The aim of our study was to assess the ability of CT to predict the resectability of pancreatic head adenocarcinomas after neoadjuvant therapy.
Section snippets
Study
Between January 2005 and December 2010, 135 patients underwent surgery in our institution with the intent of curing an adenocarcinoma of the head of pancreas. The preoperative CT scans of 80 of these patients were in our possession, either in our institutional imaging database or in the patient record. Thirty-eight of these 80 patients underwent neoadjuvant treatment because of a tumor that was considered to be “borderline” or locally advanced on the initial CT scan. Thirty-seven of 38 patients
Demographic and clinical data (Table 1)
The average time between CT and surgery was higher in the neoadjuvant group. Preoperative pancreatic biopsies, bile duct bypasses, and clinical infections (cholangitis or cholecystitis) were all significantly more frequent in the neoadjuvant group. The presence of peripancreatic inflammation (visible as a diffuse infiltration into the peripancreatic fat) was more frequently observed after neoadjuvant therapy.
Operability
In the control group, only one patient could not undergo resection because of liver
Discussion
The use of neoadjuvant therapy is commonly accepted as the initial step in the management of patients with “borderline” pancreatic head cancer to increase the likelihood of an R0 resection [8]. However, the CT evaluation of tumor responses after preoperative treatment has not been well explored. In this study, we show that the ability of CT to evaluate operability, T-staging, and histological resectability is reduced after neoadjuvant therapy. The decrease in the diagnostic specificity of the
References (25)
- et al.
Redefining resection margin status in pancreatic cancer
HPB: The Official Journal of the International Hepato Pancreato Biliary Association (Oxford)
(2009) - et al.
Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas
Journal of the American College of Surgeons
(2005) - et al.
Staging of pancreatic cancer before and after neoadjuvant chemoradiation
Journal of Gastrointestinal Surgery
(2001) - et al.
Surgical approach to the superior mesenteric artery by the Kocher maneuver: anatomy study and clinical applications
Annals of Vascular Surgery
(1987) - et al.
Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma
International Journal of Radiation Oncology, Biology, Physics
(2004) - et al.
Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?
Annals of Surgery
(2008) - et al.
Cancer statistics
CA: A Cancer Journal for Clinicians
(2010) - et al.
Assessment of complications after pancreatic surgery: a novel grading system applied to 633 patients undergoing pancreaticoduodenectomy
Annals of Surgery
(2006) - et al.
Pancreaticoduodenectomy with vascular resection: margin status and survival duration
Journal of Gastrointestinal Surgery
(2004) - et al.
Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages
PLoS Medicine
(2010)
Surgical resectability of pancreatic adenocarcinoma: CTA
Abdominal Imaging
Cited by (118)
Imaging of pancreatic ductal adenocarcinoma – An update for all stages of patient management
2024, European Journal of Radiology OpenMeta-analysis of adjuvant chemotherapy versus no adjuvant chemotherapy for resected stage I pancreatic cancer
2024, Surgery (United States)What Can We Learn About Pancreatic Adenocarcinoma from Imaging?
2022, Hematology/Oncology Clinics of North AmericaVascular resections in minimally invasive surgery for pancreatic cancer
2022, Laparoscopic, Endoscopic, and Robotic Surgery